Get started
Author

Jochen Klaus

Observed names: J Klaus, Klaus, Jochen
ORCID: 0000-0002-1434-2867
Observed ORCID: 0000-0002-1434-2867
OpenAlex ID: A5113299378
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
2023 · Brian G Feagan, Bruce E Sands, et al. · ˜The œLancet. Gastroenterology & hepatology · 246
Risankizumab for Ulcerative Colitis
2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 135
PDF
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
2024 · David T Rubin, Jessica R Allegretti, et al. · The Lancet · 113
PDF
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
2017 · William J Sandborn, Scott D Lee, et al. · Gut · 106
PDF
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
2023 · Laurent Peyrin-Biroulet, Jessica R. Allegretti, et al. · Gastroenterology · 104
PDF
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
2021 · Silvio Danese, Jean-Frederic Colombel, et al. · ˜The œLancet. Gastroenterology & hepatology · 98
PDF
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
2021 · Laurent Peyrin-Biroulet, Ailsa Hart, et al. · ˜The œLancet. Gastroenterology & hepatology · 97
PDF
Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn's Disease
2009 · Jochen Klaus, Ulrike Spaniol, et al. · BMC Gastroenterology · 81
PDF
Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease
2003 · Christian von Tirpitz, Sonja Epp, et al. · European Journal of Gastroenterology & Hepatology · 70
A Randomised, Double-blind, Placebo-controlled Trial ofTrichuris suisova in Active Crohn’s disease
2016 · Jürgen Schölmerich, Klaus Fellermann, et al. · Journal of Crohn s and Colitis · 65
PDF
Increase of bone mineral density with sodium fluoride in patients with Crohnʼs disease
2000 · Christian von Tirpitz, Jochen Klaus, et al. · European Journal of Gastroenterology & Hepatology · 55
NOD2 Polymorphism Predicts Response to Treatment in Crohn’s Disease—First Steps to a Personalized Therapy
2011 · Jan Hendrik Niess, Jochen Klaus, et al. · Digestive Diseases and Sciences · 43
PDF
Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn’s Disease
2020 · Anna-Maria Globig, Nikola Patricia Sommer, et al. · Cellular and Molecular Gastroenterology and Hepatology · 32
Safety and tolerability of spesolimab in patients with ulcerative colitis
2022 · Marc Ferrante, Peter M Irving, et al. · Expert Opinion on Drug Safety · 30
PDF
First Reported Case of Disease: Peliosis Hepatis as Cardinal Symptom of Hodgkin’s Lymphoma
2009 · Alexander Kleger, Martin Bommer, et al. · The Oncologist · 25
PDF
Mobile Apps for the Management of Gastrointestinal Diseases: Systematic Search and Evaluation Within App Stores
2022 · Eva-Maria Messner, Niklas Sturm, et al. · Journal of Medical Internet Research · 24
PDF
Comparison of superb microvascular imaging (SMI) quantified with ImageJ to quantified contrast-enhanced ultrasound (qCEUS) in liver metastases—a pilot study
2021 · Wolfgang Kratzer, Melanie Güthle, et al. · Quantitative Imaging in Medicine and Surgery · 24
PDF
Psychiatrische Notfälle auf der medizinischen Notaufnahme des Universitätsklinikums Ulm in den Jahren 2000 und 2010
2015 · Roland Freudenmann, Johannes Espe, et al. · Psychiatrische Praxis · 19
Validierung des Geriatrie-Checks zur Identifikation geriatrischer Patienten in der Notaufnahme
2020 · Tobias Gerhard, Kristina Mayer, et al. · Zeitschrift für Gerontologie und Geriatrie · 17
PDF
Ustekinumab serum concentrations are associated with clinical outcomes in Crohn’s disease – a regional multi-center pilot study
2020 · Anne Kerstin Thomann, Lucas-Alexander Schulte, et al. · Zeitschrift für Gastroenterologie · 17
A Single Dose of Intravenous Zoledronate Prevents Glucocorticoid Therapy-Associated Bone Loss in Acute Flare of Crohn's Disease, a Randomized Controlled Trial
2011 · Jochen Klaus, M M Haenle, et al. · The American Journal of Gastroenterology · 17
Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis
2008 · Simon Kreck, Jochen Klaus, et al. · PharmacoEconomics · 17
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study
2021 · Geert R D’Haens, Walter Reinisch, et al. · Inflammatory Bowel Diseases · 16
PDF
825 Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA Study
2015 · William Sandborn, Scott D. Lee, et al. · Gastroenterology · 16
Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis.
2011 · Jochen Klaus, Max Reinshagen, et al. · PubMed · 16
Works count: 63
Citation count: 1,598
H-index: 18
I10-index: 29
Year
Topic
Type